Natco Pharma announced the conclusion of the U.S. Food and Drug Administration (FDA) inspection at its Pharma Division in Kothur, Hyderabad, conducted from June 9th to June 19th, 2025.
The company received 7 observations in Form-483 upon conclusion of the inspection.
Natco Pharma is confident it will address the observations within the stipulated timeline and remains committed to cGMP compliance and supplying high-quality products.